The role of redox-related post-translational changes of complement factor H (CFH) in age-related macular degeneration

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1060323

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients with AMD experience loss of central vision and this disorder is the leading cause of blindness in those aged over 50 years in Australia. There are currently no effective treatments for dry AMD. We have identified a protein that undergoes a modification in the blood and the eyes of humans with AMD that has given us new insights into how AMD develops. Specific therapies targeting this modified protein may offer a new treatment for this important cause of blindness.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $652,019.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Optometry and Ophthalmology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

autoantibodies | complement | macular degeneration | oxidation | smoking-related diseases

Related Links